Education
About Us
Working with TipRanks
Follow Us
Definium Therapeutics (DFTX)
NASDAQ:DFTX
Total Valuation
Definium Therapeutics has a market cap or net worth of $1.48B. The enterprise value is $992.63M.
Market Cap$1.48B
Enterprise Value$992.63M
Share Statistics
Definium Therapeutics has 98,509,280 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding98,509,280
Owned by Insiders1.68%
Owned by Institutions0.04%
Financial Efficiency
Definium Therapeutics’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee―
Profits Per Employee―
Employee Count74
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of Definium Therapeutics is ―. Definium Therapeutics’s PEG ratio is 0.12.
PE Ratio―
PS Ratio0.00
PB Ratio2.03
Price to Fair Value―
Price to FCF-6.20
Price to Operating Cash Flow―
PEG Ratio0.12
Income Statement
In the last 12 months, Definium Therapeutics had revenue of ― and earned ― in profits. Earnings per share was ―.
Revenue―
Gross Profit―
Operating Income―
Pretax Income―
Net Income―
EBITDA―
Earnings Per Share (EPS)―
Cash Flow
In the last 12 months, operating cash flow was ― and capital expenditures ―, giving a free cash flow of ― billion.
Operating Cash Flow―
Free Cash Flow―
Free Cash Flow per Share―
Dividends & Yields
Definium Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.59
52-Week Price Change109.61%
50-Day Moving Average12.69
200-Day Moving Average9.74
Relative Strength Index (RSI)63.46
Average Volume (3m)2.02M
Important Dates
Definium Therapeutics upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Definium Therapeutics as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―
Taxes
In the past 12 months, Definium Therapeutics has paid ― in taxes.
Income Tax―
Effective Tax Rate―
Enterprise Valuation
Definium Therapeutics EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Definium Therapeutics has ― in cash and marketable securities with $0.00 in debt, giving a net cash position of ― billion.
Cash & Marketable Securities―
Total Debt$0.00
Net Cash―
Net Cash Per Share―
Tangible Book Value Per Share―
Margins
Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin―
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for Definium Therapeutics is $30.80, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$30.80
Price Target Upside104.65% Upside
Analyst ConsensusStrong Buy
Analyst Count10
Revenue Growth Forecast―
EPS Growth Forecast0.69%